MRK vs MSFT: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
VS
Microsoft Corporation · Technology
$379.40
+45.0% upside to fair value
Grade A
High Quality
QuantHub Verdict
MSFT has more upside to fair value
(+45.0%).
MSFT trades at a lower forward P/E
(22.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MSFT |
| Current Price |
$113.87 |
$379.40 |
| Fair Value Estimate |
$100.14 |
$550.13 |
| Upside to Fair Value |
-12.1%
|
+45.0%
|
| Market Cap |
$281.2B |
$2,818.3B |
| Forward P/E |
32.0x
|
22.5x
|
| EV / EBITDA |
17.3x
|
14.2x
|
| Price / Sales |
4.3x
|
8.9x
|
| Price / FCF |
19.9x
|
38.6x
|
| Revenue Growth YoY |
+4.3%
|
+18.3%
|
| Gross Margin |
75.9%
|
68.3%
|
| Operating Margin |
27.6%
|
46.8%
|
| Return on Equity |
17.9%
|
33.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.02%
|
2.59%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Microsoft Corporation is a leading global technology company specializing in cloud computing, productivity software, and enterprise platforms. The company benefits from a very strong and widening competitive moat supported by scale, switching costs, an integrated ecosystem, and disciplined capital allocation including large buybacks and dividends. Its business quality is high, demonstrated by a 3…
Accumulation Zones
| Metric |
MRK |
MSFT |
| Zone Low |
$75.11 |
$412.60 |
| Zone High |
$85.12 |
$467.61 |
| In Buy Zone? |
No
|
Yes
|